Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Horvath

Showing results (231-240 of 279) with videos related to

Pageof 28
Sort By:
European Urology|June 4, 2020
Combined Cell-free DNA and RNA Profiling of the Androgen Receptor: Clinical Utility of a Novel Multianalyte Liquid Biopsy Assay for Metastatic Prostate CancerHeidi Fettke, Edmond M Kwan, Maria M Docanto, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2026
AI-Based Pathology classifier Predicts Sensitivity to Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer: A Biomarker Analysis of the ENZAMET TrialSebastian Medina, Naoto Tokuyama, Vaishnavi Putcha, et al.
JCO Precision Oncology|July 12, 2021
Plasma Cell-Free DNA Profiling of PTEN-PI3K-AKT Pathway Aberrations in Metastatic Castration-Resistant Prostate CancerEdmond M Kwan, Chao Dai, Heidi Fettke, et al.
British Journal of Cancer|April 14, 2015
Cytokine profiling of docetaxel-resistant castration-resistant prostate cancerK L Mahon, H-M Lin, L Castillo, et al.
Epigenetics & Chromatin|May 30, 2018
Guidelines for whole genome bisulphite sequencing of intact and FFPET DNA on the Illumina HiSeq X TenShalima S Nair, Phuc-Loi Luu, Wenjia Qu, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|November 25, 2010
Epigenetic deregulation across chromosome 2q14.2 differentiates normal from prostate cancer and provides a regional panel of novel DNA methylation cancer biomarkersJames Devaney, Clare Stirzaker, Wenjia Qu, et al.
Elife|July 21, 2020
Human DECR1 is an androgen-repressed survival factor that regulates PUFA oxidation to protect prostate tumor cells from ferroptosisZeyad D Nassar, Chui Yan Mah, Jonas Dehairs, et al.
British Journal of Cancer|November 23, 2013
Adjuvant chemotherapy in elderly patients with pancreatic cancerA M Nagrial, D K Chang, N Q Nguyen, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 15, 2006
Aberrant neuropeptide Y and macrophage inhibitory cytokine-1 expression are early events in prostate cancer development and are associated with poor prognosisKrishan K Rasiah, James G Kench, Margaret Gardiner-Garden, et al.
Alimentary Pharmacology & Therapeutics|September 3, 2011
Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn's diseaseL S Kiss, T Szamosi, T Molnar, et al.
Pageof 28

Showing results (231-240 of 279) with videos related to

Sort By:
Pageof 28
European Urology|June 4, 2020
Combined Cell-free DNA and RNA Profiling of the Androgen Receptor: Clinical Utility of a Novel Multianalyte Liquid Biopsy Assay for Metastatic Prostate CancerHeidi Fettke, Edmond M Kwan, Maria M Docanto, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2026
AI-Based Pathology classifier Predicts Sensitivity to Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer: A Biomarker Analysis of the ENZAMET TrialSebastian Medina, Naoto Tokuyama, Vaishnavi Putcha, et al.
JCO Precision Oncology|July 12, 2021
Plasma Cell-Free DNA Profiling of PTEN-PI3K-AKT Pathway Aberrations in Metastatic Castration-Resistant Prostate CancerEdmond M Kwan, Chao Dai, Heidi Fettke, et al.
British Journal of Cancer|April 14, 2015
Cytokine profiling of docetaxel-resistant castration-resistant prostate cancerK L Mahon, H-M Lin, L Castillo, et al.
Epigenetics & Chromatin|May 30, 2018
Guidelines for whole genome bisulphite sequencing of intact and FFPET DNA on the Illumina HiSeq X TenShalima S Nair, Phuc-Loi Luu, Wenjia Qu, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|November 25, 2010
Epigenetic deregulation across chromosome 2q14.2 differentiates normal from prostate cancer and provides a regional panel of novel DNA methylation cancer biomarkersJames Devaney, Clare Stirzaker, Wenjia Qu, et al.
Elife|July 21, 2020
Human DECR1 is an androgen-repressed survival factor that regulates PUFA oxidation to protect prostate tumor cells from ferroptosisZeyad D Nassar, Chui Yan Mah, Jonas Dehairs, et al.
British Journal of Cancer|November 23, 2013
Adjuvant chemotherapy in elderly patients with pancreatic cancerA M Nagrial, D K Chang, N Q Nguyen, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 15, 2006
Aberrant neuropeptide Y and macrophage inhibitory cytokine-1 expression are early events in prostate cancer development and are associated with poor prognosisKrishan K Rasiah, James G Kench, Margaret Gardiner-Garden, et al.
Alimentary Pharmacology & Therapeutics|September 3, 2011
Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn's diseaseL S Kiss, T Szamosi, T Molnar, et al.
Pageof 28